figshare
Browse
iceh_a_1334799_sm6322.docx (42.48 kB)

Genetic screening of SCNN1B and SCNN1G genes in early-onset hypertensive patients helps to identify Liddle syndrome

Download (42.48 kB)
Version 2 2018-01-09, 12:32
Version 1 2017-07-18, 13:18
journal contribution
posted on 2018-01-09, 12:32 authored by Kun-Qi Yang, Chao-Xia Lu, Peng Fan, Ying Zhang, Xu Meng, Xue-Qi Dong, Fang Luo, Ya-Xin Liu, Hui-Min Zhang, Hai-Ying Wu, Jun Cai, Xue Zhang, Xian-Liang Zhou

Background: Liddle syndrome is an autosomal dominant form of monogenic hypertension. Phenotypic variability makes it difficult to identify patients with Liddle syndrome, resulting in misdiagnosis and severe complications at early age. Objectives: To identify mutation in SCNN1B and SCNN1G genes in an adolescent with suspicious Liddle syndrome and his family members and to explore the screening target subjects of Liddle syndrome. Methods: Genetic analysis of the C-terminus of SCNN1B and SCNN1G genes was conducted in an adolescent, with treatment-resistant hypertension and hypokalemia, who was suspected of having Liddle syndrome, and his family members. A Medline research of the reported cases with Liddle syndrome was also performed. Results: A recurrent SCNN1B mutation, c.1853C>A (p.P618H), was detected in the 19-year-old male patient, and family screening identified five additional members who were heterozygous for the mutation. The diagnosis of Liddle syndrome was made in all affected individuals. Despite the phenotypic variability, a systematic review of 54 reported index cases revealed the early-onset hypertension, aged no more than 30 years, as a common feature. Conclusions: Genetic screening for Liddle syndrome should be considered in hypertensive subjects with early penetrance, maybe no more than 30 years, after exclusion of common secondary causes of hypertension.

Funding

This work was supported by CAMS Innovation Fund for Medical Sciences (2016-I2M-1-002), National Natural Science Foundation of China (81541010), the National Key Research and Development Program of China (2016YFC1300100), Beijing Municipal Science and Technology Commission (Z151100003915078), Beijing Nova Program (xx2017022), the Capital Medical Development Scientific Research Fund (2014-4-4035), PUMC Youth Fund and the Fundamental Research Funds for the Central Universities (3332015205), and PUMC Graduate Innovation Fund (10023-1002-1001).

History